Anthrax Antimicrobial One Goal of Paradigm Genetics, VDDI Collaboration

Feb 26, 2002

NEW YORK, Feb. 26 - Paradigm Genetics and VDDI Pharmaceuticals will research and develop novel antibiotics for certain bacteria that may be used as bioterror agents, the companies said on Tuesday.

Terms of the deal call for Paradigm to supply its MetaVantage platform. VDDI, meanwhile, will provide samples of a new class of antimicrobials recently discovered at the University of Alabama.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Breaking News

The Scan

Persistent Gap

Researchers examine the gap in funding between researchers and research institutions, ScienceInsider reports

Puppies' Past

By sequencing two ancient dog genomes, researchers from the US and Germany suggest that dogs were domesticated in a single event, the Washington Post reports.

This Week in Genome Research

In Genome Research this week: population dynamics of E. coli infection, lncRNA expression changes in macaque aging, and more.

Testing for Complications

Noninvasive prenatal testing can uncover pregnancies at risk of miscarriage, New Scientist reports.

Main menu